A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

PHASE3RecruitingINTERVENTIONAL

Enrollment

510

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

October 31, 2027

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

AK117 in combination with AK112

Following a predefined dose and date.

DRUG

Placebo in combination with Pembrolizumab

Following a predefined dose and date.

Trial Locations (2)

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

West China Hospital of Sichuan University, Chengdu